Home  »  Company News   »  Adaptimmune Therapeutics plc (ADAP) poses a Brand-...

Adaptimmune Therapeutics plc (ADAP) poses a Brand-New Opportunity for Investors with beta value of 2.01

As on October 11, 2021, Adaptimmune Therapeutics plc (NASDAQ: ADAP) got off with the flyer as it spiked 1.17% to $5.18. During the day, the stock rose to $5.28 and sunk to $5.04 before settling in for the price of $5.12 at the close. Taking a more long-term approach, ADAP posted a 52-week range of $3.37-$9.31.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


>> 7 Top Picks for the Post-Pandemic Economy << 

In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -15.10%. Meanwhile, its Annual Earning per share during the time was -24.90%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 30.10%. This publicly-traded company’s shares outstanding now amounts to $155.71 million, simultaneously with a float of $126.69 million. The organization now has a market capitalization sitting at $811.60 million. At the time of writing, stock’s 50-day Moving Average stood at $4.85, while the 200-day Moving Average is $5.02.

If we measure the efficiency of the company that is accounted for 462 employees. It has generated 8,567 per worker during the last fiscal year. Meanwhile, its income per employee was -281,584. The stock had 0.19 Receivables turnover and 0.01 Total Asset turnover. For the Profitability, stocks operating margin was -3839.26 and Pretax Margin of -3773.93.

Adaptimmune Therapeutics plc (ADAP) Ownership Facts and Figures

Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Adaptimmune Therapeutics plc’s current insider ownership accounts for 0.10%, in contrast to 79.40% institutional ownership. According to the most recent insider trade that took place on Sep 01, this organization’s Chief Executive Officer sold 2,782 shares at the rate of 5.20, making the entire transaction reach 14,452 in total value, affecting insider ownership by 3,070. Preceding that transaction, on Aug 02, Company’s Chief Patient Supply Officer sold 2,939 for 3.58, making the whole transaction’s value amount to 10,536. This particular insider is now the holder of 4,873 in total.

Adaptimmune Therapeutics plc (ADAP) Earnings and Revenue Records

If we go through the results of last quarter, which was made public on 6/29/2021, the company posted -$0.24 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -$0.24) by $0. This company achieved a net margin of -3286.81 while generating a return on equity of -55.97. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.

Adaptimmune Therapeutics plc’s EPS increase for this current 12-month fiscal period is 30.10% and is forecasted to reach -1.00 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 1.00% through the next 5 years, which can be compared against the -24.90% growth it accomplished over the previous five years trading on the market.

Adaptimmune Therapeutics plc (NASDAQ: ADAP) Trading Performance Indicators

Let’s observe the current performance indicators for Adaptimmune Therapeutics plc (ADAP). It’s Quick Ratio in the last reported quarter now stands at 8.10. The Stock has managed to achieve an average true range (ATR) of 0.37. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 130.90.

In the same vein, ADAP’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.96, a figure that is expected to reach -0.27 in the next quarter, and analysts are predicting that it will be -1.00 at the market close of one year from today.

Technical Analysis of Adaptimmune Therapeutics plc (ADAP)

Through scrutinizing the latest numbers posted by the [Adaptimmune Therapeutics plc, ADAP], it can be observed that its last 5-days Average volume of 0.46 million was lower the volume of 1.27 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 15.75% While, its Average True Range was 0.30.

>> 7 Top Picks for the Post-Pandemic Economy << 

Raw Stochastic average of Adaptimmune Therapeutics plc (ADAP) in the period of the previous 100 days is set at 51.86%, which indicates a major rise in contrast to 15.56% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 47.60% that was lower than 71.96% volatility it exhibited in the past 100-days period.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

Sign up for Our Newsletter Now! Discover which stocks to trade!
100% Free. Stop Anytime. No Spam